French biotechnology company Genticel, a leading developer of therapeutic vaccines, recently announced it has licensed its Vaxiclase technology to the Serum Institute of India, Ltd. (SIIL).
The institute will use Vaxiclase as a component in acellular multivalent combination vaccines with a focus on pertussis antigens. Bordetella pertussis is the bacterium that causes whooping cough.
As part of the deal, Genticel is eligible for up to $57 million in upfront, development and sales milestone payments from SIIL, in addition to single-digit royalties on net sales. Other financial terms were not disclosed.
"We have been closely monitoring the challenges related to resurgence of pertussis,” SIIL Executive Director and CEO Adar C. Poonawalla said. “Based on our analysis, we are sure the collaboration with Genticel and use of Vaxiclase will play a key role in improving the acellular pertussis component-based combination vaccine."
Genticel CEO Benedikt Timmerman is also pleased with the agreement.
"We are very satisfied with our partnership with Serum Institute of India, the largest vaccine producer in the world,” Timmerman said. “This deal opens an entirely new field of applications for Vaxiclase, which complements our core activities in the HPV field. Besides this deal's commercial interest, we are proud to be associated with a development program that may lead to one of the most widely supplied combination vaccines worldwide."
Timmerman sees additional benefits in the alliance beyond the immediate benefits in addressing pertussis.
"The deal will also provide Genticel with access to improved production methods that the Serum Institute may implement on our Vaxiclase platform," he said. "Given Serum's extensive experience and track record in this area, this is of strategic value to Genticel.”